Aurobindo Pharma falls on FDA warning letter

Aurobindo Pharma falls on FDA warning letter following an inspection at its Telangana facility. The FDA issued the letter citing data integrity issues, potentially impacting exports to the US. This regulatory setback could delay approvals for pending products.

📊 STOCKS: $AUROPHARMA | 🏢 SECTOR: Pharma | #HIGHIMPACT #FDA